GLP-1 Clinical Trials in Parkinson's Disease
Clinical results across GLP-1 receptor agonists in PD have been mixed, with some trials meeting primary endpoints and others failing. The overall pattern of positive preclinical and epidemiological evidence alongside inconclusive clinical…
1 sources - 3 claims
Clinical results across GLP-1 receptor agonists in PD have been mixed, with some trials meeting primary endpoints and others failing. The overall pattern of positive preclinical and epidemiological evidence alongside inconclusive clinical data supports rigorous testing of a structurally distinct molecule delivered via a different route. The inconsistency between the phase 2 and phase 3 exenatide trials may reflect differences in injection device, dosing continuity, or patient subgroup composition.